Fluorescence-detection size-exclusion chromatography specifically detects autoantibodies targeting the ganglionic acetylcholine receptor in patients with autoimmune autonomic ganglionopathy.

Autor: Baxter L; Department of Neurobiology, University of California San Diego, United States., Hopkins S; Department of Neurology, University of Texas Southwestern Medical Center, United States., O'Connor KC; Department of Neurology, Yale University School of Medicine, United States; Department of Immunobiology, Yale University School of Medicine, United States., Pham MC; Department of Neurology, Yale University School of Medicine, United States., Nowak RJ; Department of Immunobiology, Yale University School of Medicine, United States., Monson NL; Department of Neurology, University of Texas Southwestern Medical Center, United States., Blackburn K; Department of Neurology, University of Texas Southwestern Medical Center, United States., Hibbs RE; Department of Neurobiology, University of California San Diego, United States; Department of Pharmacology, University of California San Diego, United States., Vernino S; Department of Neurology, University of Texas Southwestern Medical Center, United States., Noviello CM; Department of Neurobiology, University of California San Diego, United States. Electronic address: conoviello@ucsd.edu.
Jazyk: angličtina
Zdroj: Journal of neuroimmunology [J Neuroimmunol] 2024 Nov 15; Vol. 396, pp. 578454. Date of Electronic Publication: 2024 Sep 08.
DOI: 10.1016/j.jneuroim.2024.578454
Abstrakt: Autoimmune autonomic ganglionopathy (AAG) is a rare disease wherein autoantibodies target the ganglionic acetylcholine receptor (gAChR). Current diagnosis in the United States depends upon clinical symptoms and positive autoantibody detection using a radioimmunoprecipitation assay (RIA). Here we offer a proof-of-principle study on an alternative method, fluorescence-detection size-exclusion-chromatography (FSEC). We show FSEC can detect autoantibodies against gAChR from patient sera but not healthy controls or samples from other autoimmune diseases. We compare FSEC to RIA and find good correlation. We discuss potential advantages of using FSEC as an alternative or as a first-step diagnostic prior to pursuing existing methodologies.
Competing Interests: Declaration of competing interest SV has received compensation as a consultant for argenx, Alterity, Amneal, Catalyst and LabCorp and has received research support from Quest Diagnostics (through a licensing contract). NM has received compensation from Genentech, Inc. as a member of the steering committee for CHIMES and is a co-founder of GenrAb, Inc.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: